Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.

User is on vacation in Greece and wants to buy tretinoin or isotretinoin to improve Minoxidil absorption. They are considering isotretinoin since it is available over-the-counter in Greece but requires a prescription back home.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

A 34-year-old underwent a hair transplant with 5,250 grafts, stem cell therapy, and PRP at Dr. Hakan Clinic in Istanbul, without using Minoxidil or Finasteride. Despite initial concerns about the hairline design, the user is optimistic about the results and plans to update progress over time.

User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.

The conversation discusses the anticipation for updates on GT20029, a potential hair loss treatment. Users also mention using Minoxidil, finasteride, and RU58841.

The conversation is about the availability of Koshine826 PRO 1% for hair loss treatment. The discussion includes Minoxidil, finasteride, and RU58841.

Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.

The user is 10 days post-hair transplant, pleased with the results so far, and hopes for increased density. The procedure was done at Vanity Hospital in Istanbul, with around 3400-3750 grafts used.

The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses using isotretinoin (Accutane) to reduce scalp oiliness and manage scalp issues like seborrheic dermatitis, inflammation, and chronic itch. A user shares that taking 20mg of Accutane every other day effectively reduces oily hair and skin.

Hair loss treatments RU and topical spironolactone were compared. No specific results or conclusions were provided.

A user shared their 12-month update after a 5,800-graft hair and beard transplant performed by Dr. Tulunay in Istanbul, using Sapphire FUE and DHI techniques. The user noted significant growth around months 8-9 and expressed satisfaction with the results.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

A user is developing an AI-powered app for hair loss that includes features like hair loss stage detection and hairline tracking. They seek feedback to ensure the app is useful and emphasize privacy and affordability.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

User seeks reputable international finasteride seller due to dermatologists refusing prescription. Dermatologists suggested PRP or exosomes instead.

A 24-year-old uses microneedling, tretinoin, topical and oral minoxidil, and oral finasteride for hair growth, noticing baby hair growth and initial side effects that resolved. Another user shares a similar regimen, excluding finasteride.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.